Founding offer · lifetime membership for a single £24, exclusive to our first members · closes 20 June Claim your place →
Global Research Partnerships £24 Lifetime Log inCreate free account

Funded Projects › FP7

PREHDICT · health-economic modelling of PREvention strategies for Hpv-related Diseases in European CounTries

FP7Status: CLOSED1 May 201030 April 2013EU funding €2,963,532

The goals of the PREHDICT study are to determine prerequisites and strategies for vaccination in European countries and to predict the impact of vaccination on screening programmes. To achieve these goals, a multiple HPV type transmission model will be built to describe the type-specific incidence and clearance of HPV infections. This model will be linked to an individual-based simulation model used for modelling the impact of screening. For HPV-related diseases other than cervical cancer and genital warts, Markov models will be developed after critical review of the role of HPV. In the PREHDICT study, country-specific cost-effectiveness analyses will be performed for the vaccination and include determination of the vaccination age, the number of doses, the vaccination population, and the optimal catch-up vaccination age. Furthermore, the impact of vaccination on screening programmes will be assessed. This involves determination of the screening technology, screening frequency, and follow-up management of test-positive women. Special attention will be given to screening attendance and its relation to vaccination attendance. To have models with strong empirical support, the PREHDICT team will collect the most updated data on HPV infection, HPV-related disease, life-style factors, and demographics. Furthermore, HPV-type specific analyses will be performed on the outcomes of a vaccination trial, 3 large screening trials, and one self-sampling trial for screening non-attenders. By meta-analytical techniques, results will be pooled. The costs involved in the calculations will include the costs of organizing, running, and monitoring a vaccination and/or screening programme. The results of the PREHDICT study will be published in international peer-reviewed journals, posted on the WHO HPV information centre website and will also be systematically disseminated to all major stakeholders, in particular to decision makers at European, national and sub-national levels.

Consortium · 13 organisations

coordinator

STICHTING VU

NL · €878,405

participant

LUNDS UNIVERSITET

SE · €23,810

participant

INSTITUT SCIENTIFIQUE DE SANTE PUBLIQUE

BE · €252,664

participant

IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE

UK · €162,668

participant

INSTITUT CATALA D'ONCOLOGIA

ES · €390,302

participant

TAMPEREEN YLIOPISTO

FI · €298,538

participant

AZIENDA OSPEDALIERA SAN GIOVANNI BATTISTA DI TORINO

IT · €335,600

participant

VERENIGING VOOR CHRISTELIJK HOGER ONDERWIJS WETENSCHAPPELIJK ONDERZOEK EN PATIENTENZORG

NL

participant

LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE ROYAL CHARTER

UK · €264,107

participant

AZIENDA OSPEDALIERA CITTA DELLA SALUTE E DELLA SCIENZA DI TORINO

IT

participant

KAROLINSKA INSTITUTET

SE · €289,890

participant

European Cervical Cancer Asociation

FR · €67,548

participant

FUNDACIO INSTITUT D'INVESTIGACIO BIOMEDICA DE BELLVITGE

ES

Research fields

View the official record on CORDIS →

← Find collaborators and more funded projects

Source: CORDIS, Publications Office of the European Union. Global Research Partnerships surfaces open EU research data to help you find collaborators; we are not affiliated with the European Union.